Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGynecological OncologySarcomasDiseaseEndometrial CancerSubgroupICD10C54.1MeSHCarcinosarcomaSequenceChemotherapyChemo-substanceCisplatinIfosfamideChemo-substanceCisplatinIfosfamideChemo-substanceCisplatinIfosfamideChemo-substanceCisplatinIfosfamideNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances8Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Gastrointestinal ToxicityInfectionsNeuropathy only studiesPublicationAuthorWolfson AHDiseaseKarzinosarkom des Uterus, FIGO-Stadium I-IVOriginSylvester Cancer Center, University of Miami Miller School of Medicine, Miami, USAProtocols in Revision 1 protocol foundProtocols under revision.Ifosfamide 1.5 / Cisplatin 20, Uterine Carcinosarcoma, adjuvant (PID1584 V1.1)
